徐兵河，1958年生，籍贯湖北，肿瘤内科学家，肿瘤医院主任医师，博士生导师。1977年考入湖北医科大学（现武汉大学）医学专业，1982年获得学士学位。1984年在中国协和医科大学肿瘤学专业攻读硕士学位，从事肿瘤药物作用机制研究。1996年在中国协和医科大学肿瘤学专业攻读博士学位，从事肿瘤药物临床研究。1991年进入美国迈阿密大学医学院进行博士后研究工作，主要研究肿瘤多药耐药机制及其逆转。 1994年为副主任医师，1998年破格晋升主任医师，2021年当选中国工程院院士。

长期致力于肿瘤内科临床和相关基础研究，重点是乳腺癌的应用基础、临床及转化等关键技术研究与抗肿瘤新药研发。

1. Binghe Xu#*, Qingyuan Zhang, Pin Zhang,Xichun Hu, Wei Li, Zhongsheng Tong, Tao Sun, Yuee Teng, Xinhong Wu, Quchang Ouyang, Xi Yan, Jing Cheng, Qiang Liu, Jifeng Feng, Xiaojia Wang, Yongmei Yin, Yanxia Shi, Yueyin Pan, Yongsheng Wang, Weimin Xie, Min Yan, Yunjiang Liu, Ping Yan, Fei Wu, Xiaoyu Zhu, and Jianjun Zou. Dalpiciclib or placebo plus fulvestrant in pretreated hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 study. 2021,Nature Medicine, 7(11): 1904-1910. (IF 55.4, PIII)

2.Ying Fan#,Tao Sun, Zhimin Shao, Qingyuan Zhang, Quchang Ouyang, Zhongsheng Tong, Shusen Wang, Yang Luo, Yuee Teng, Xiaojia Wang, Shu Wang,Qiang Liu, ifeng Feng, Kunwei Shen, Yanqiu Song,Jiayu Wang, Fei Ma, Qing Li, Pin Zhang, Binghe Xu*. Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators A Phase 2 Randomized Clinical Trial. JAMA Oncol, 2021, 7(10): E1-E7. (IF 31.7)

3.Yuanyuan Zhang#, Hongyan Chen#, Hongnan Mo#, Xueda Hu, Ranran Gao, Yahui Zhao, Baolin Liu, Lijuan Niu, Xiaoying Sun, Xiao Yu, Yong Wang, Qing Chang, Tongyang Gong, Xiuwen Guan, Ting Hu, Tianyi Qian, Binghe Xu*, Fei Ma*, Zemin Zhang*, Zhihua Liu*. Single-cell analyses reveal key immune cell subsets associated with response to PDL1 blockade in triple negative breast cancer. Cancer Cell, 2021,39: 1-13. (IF 31.7)

4.Binghe Xu#*, Min Yan#, Fei Ma#, Xichun Hu, Jifeng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Yuanting Gu, Qianjun Chen, Jinping Liu, Jing Cheng, Cuizhi Geng, Shukui Qin, Shusen Wang, Jinsong Lu,Kunwei Shen, Qiang Liu, Xiaojia Wang, Hong Wang, Ting Luo, Jin Yang, Yudong Wu, Zhiyong Yu, Xiaoyu Zhu, Chunxia Chen, and Jianjun Zou. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol 2021, 22(3)：351-360. (IF 41.3, PIII, R)

5.B. Xu#*, T. Sun#, Q Zhang#, P zhang#, Z Yuan, X Wang, S Cui, Y Teng, X-C Hu, J Yang, H Pan, Z Tong, H Li, Q Yao,Y Wang, Y Yin, P Sun, H Zheng, J Cheng, J Lu, B Zhang, C Geng, J Liu, K Shen, S Yu, H Li, L Tang, R Qiu. Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial.2021, Ann Oncol, 32(2):218-228. (IF 32.9, PIII)

6.Fei Ma#, Quchang Ouyang, Wei Li, Zefei Jiang, Zhongsheng Tong, Yunjiang Liu, Huiping Li,Shiying Yu, Jifeng Feng, Shusen Wang,Xichun Hu, Jianjun Zou, Xiaoyu Zhu, Binghe Xu*. Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.2019, J Clin Oncol, 37(29): 2610-2619. (IF 26.3, C100, ESI)

7.Qiao Li#, Xiuwen Guan#, Shanshan Chen, Zongbi Yi, Bo Lan; Puyuan Xing; Ying Fan, Jiayu Wang, Yang Luo, Peng Yuan, Ruigang Cai, Pin Zhang, Qing Li, Dafang Zhong, Yifan Zhang, Jianjun Zou, Xiaoyu Zhu, Fei Ma, Binghe Xu*. Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial.2019,Clin Cancer Res, 25(17):5212-5220. (IF: 10.107)

8.Fei Ma#, Qiao Li#, Shanshan Chen, Wenjie Zhu, Ying Fan, Jiayu Wang, Yang Luo, Puyuan Xing, Bo Lan, Meiying Li, Zongbi Yi, Ruigang Cai, Peng Yuan, Pin Zhang, Qing Li, Binghe Xu*. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human EGFR2-Positive Metastatic Breast Cancer. 2017, J Clin Oncol, 35(27): 310-316. (IF 24.0, C100)

9.Pin Zhang#, Tao Sun; Qingyuan Zhang; Zhongyu Yuan; Zefei Jiang,; Xiao Jia Wang, Shude Cui ,Yuee Teng, Xi-Chun Hu, Junlan Yang, Hongming Pan, Zhongsheng Tong, Huiping Li, Qiang Yao, Yongshen Wang, Yongmei Yin, Ping Sun, Hong Zheng, Jing Cheng,; Jinsong Lu, Baochun Zhang,Cuizhi Geng, Jian Liu, Roujun Peng, Min Yan, Shaohua Zhang, Jian Huang, Li Tang, Rongguo Qiu, Binghe Xu*. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes. 2017, 17(3):357-366. Lancet Oncol (IF 36.4, PIII)

10.Nadia Harbeck#, Chiun-Sheng Huang, Sara Hurvitz, Dah-Cherng Yeh, Zhimin Shao, Seock-Ah Im, Kyung Hae Jung, Kunwei Shen, Jungsil Ro, Jacek Jassem, Qingyuan Zhang, Young-Hyuck Im, Marek Wojtukiewicz, Qiang Sun, Shin-Cheh Chen, Rainer-Georg Goeldner, Martina Uttenreuther-Fischer, Binghe Xu*, Martine Piccart-Gebhart. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer.  2016, Lancet Oncol, 17 (3):357-366. (IF 33.9, PIII)